Product Description
Bayer was developing bay86-5300, an oral drug, for the treatment of Dysmenorrhea (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01892904)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Endometriosis|Contraception|Acne Vulgaris|Other|Premenstrual Dysphoric Disorder|Depressive Disorder, Major|Pain Unspecified
Phase 2: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT02617537 | P3 |
Withdrawn |
Other |
2017-09-01 |
|
JapicCTI-121984 | P3 |
Completed |
Endometriosis |
2015-02-01 |
|
JapicCTI-132193 | P3 |
Completed |
Unknown |
2015-02-01 |
|
NCT01892904 | P3 |
Completed |
Pain Unspecified |
2015-01-01 |